glutamate modulation – Discover Pharma

Welcome to Discover Pharma! Today is : October 31, 2026

glutamate modulation

Central Nervous System,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas
Newron completes Phase 3 trial enrolment in schizophrenia
Newron Pharmaceuticals has completed enrolment of 618 patients in its [...]

October 29, 2026
Biotech & Pharma Business,Central Nervous System,Clinical & Regulatory
Newron secures up to EUR 38 million to advance Phase 3 evenamide program in treatment-resistant schizophrenia
Newron Pharmaceuticals has secured up to EUR 38 million in [...]

May 5, 2026
Central Nervous System,Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas
Newron publishes data showing clinically meaningful benefits of evenamide in treatment-resistant schizophrenia
Newron Pharmaceuticals has published peer-reviewed clinical data demonstrating that evenamide, [...]

May 5, 2026
Central Nervous System,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas
Preclinical study shows evenamide targets schizophrenia pathology in the hippocampus
Newron Pharmaceuticals has highlighted new preclinical findings published in Neuropsychopharmacology [...]

May 5, 2026

This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.

OK